ICU医疗 2025年季度报告

Emerging growth companyIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act):Yes☐Nox regulations; tariffs; as well as plans and objectives of management for future operations, are forward-looking statements. Without limiting theforegoing, in some cases, you can identify forward-looking statements by terms such as “aim,” “may,” “will,” “should,” “expect,” “exploring,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “seeks,” or “continue”or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. No forward-looking statement is a guarantee of future results, performance, or achievements, and one should avoid placing undue reliance on suchThe forward looking statements in this Quarterly Report on Form 10-Q are only predictions and are based largely on our currentexpectations and projections about future events and financial trends that we believe may affect our business, financial condition and results ofoperations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number ofknown and unknown risks, uncertainties and assumptions, including without limitation, the following: of personnel;•failure to protect our information technology systems against security breaches, service interruptions, or misappropriation of data;•our exposure to risks related to foreign currency exchange rates;•damage to any of our manufacturing facilities or disruption to our supply chain network; •significant sales through our distributors;•additional risks from international sales, related to competition with larger international companies and established local companiesand our possibly higher cost structure;•actual or perceived failures to comply with foreign, federal, and state data privacy and security laws, regulations and standards, or certain fraud and abuse and transparency laws;•our failure to defend and enforce our patents or other proprietary rights and the cost of enforcing and of defending patent claims orclaims of other proprietary rights; and expiration of our patents;•our failure to effectively complete the integration of our business resulting from the Smiths Medical acquisition or manage our growthand changes to our business resulting from any other future acquisitions;•our use of a significant portion of our cash on hand and incurrence of a substantial amount of debt to finance the Smiths Medicalacquisition, which could adversely affect our business, including by restricting our ability to engage in additional transactions or incur activity.For a more detailed discussion of these and other factors, see the information under the sections entitled “Summary Risk Factors,” PartI. Item 1A. “Risk Factors” and Part II. Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in ourAnnual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “2024 Annual Report on Form 10-K”) filed with the Securitiesand Exchange Commission (the “SEC”), and the sections in this Quarterly Report on Form 10-Q entitled Part II. Item 1A “Risk Factors” andPart I. Item 2 “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in each case as updated by our 2 Accrued liabilitiesIncome taxes, including excess tax benefits and deferred income taxes Net cash provided by operating activitiesCASH FLOWS FROM INVESTING ACTIVITIES:Purchases of property, plant and equipment(14,621)Proceeds from sale of assets42Intangible asset additions(2,232)Proceeds from sale and maturities of investment securities—Net cash used in investing activities(16,811) Effect of exchange rate changes on cash2,958NET DECREASE IN CASH AND CASH EQUIVALENTS(18,862)CASH AND CASH EQUIVALENTS, beginning of period308,566CASH AND CASH EQUIVALENTS, end of period$289,704$The accompanying notes are an integral part of these condensed consolidated financial statements. 7 Three months endedMarch 31,2025SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING ACTIVITIES:Purchases of property, plant, and equipment in accounts payable$10,247$ 8 Note 1:Basis of Presentation Delaware corporation, have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S.")and pursuant to the rulesand regulations of the Securities and Exchange Commission (“SEC”) and reflect all adjustments, consisting of only normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the consolidated results for the interimperiods presented. Results for the interim period are not necessarily indicative of results for the full year.